Vanderbilt University and Bayer to evaluate new drug candidates for kidney diseases


Vanderbilt University Medical Center (VUMC) and Bayer are set to form a strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases.

The five-year drug discovery project is aimed at accelerating the translation of new approaches from the laboratory to pre-clinical development.

Furthermore, the goal is to develop two new investigational drugs addressing the medical need of end-stage renal disease (ESRD) within the time frame of the alliance.

VUMC nephrology division director Raymond Harris said: “We are excited about this partnership with Bayer to develop new drugs and novel therapies to target patients who have kidney diseases and to stop their progression.”

“At least 30 million people in the US have kidney disease, and it is greater in the African-American, Hispanic, Native American and Pacific Islander populations.

"We are excited about this partnership with Bayer to develop new drugs and novel therapies to target patients who have kidney diseases and to stop their progression."

“We have a severe shortage and limited number of kidneys available through living and cadaver donors. We don’t have enough options. The best thing would be to never have to go on dialysis.”

Under the agreement, VUMC and Bayer will jointly conduct research activities such as target validation, assay development and lead optimisation.

The companies will also contribute personnel and infrastructure in a bid to address important scientific questions.

Through the project, Vanderbilt will work on various other projects to develop a range of potential compounds that will be tested and used on patients.

Working alongside the university’s institute for chemical biology, the division of nephrology will soon prepare a treatment for clinical trial testing.